Synonym
Salinomycin Sodium; Salinomycin sodium salt; Sodium salinomycin; Salinomycin (sodium salt);
IUPAC/Chemical Name
sodium;(2R)-2-[(2R,5S,6R)-6-[(2S,3S,4S,6R)-6-[(3S,5S,7R,9S,10S,12R,15R)-3-[(2R,5R,6S)-5-ethyl-5-hydroxy-6-methyloxan-2-yl]-15-hydroxy-3,10,12-trimethyl-4,6,8-trioxadispiro[4.1.57.35]pentadec-13-en-9-yl]-3-hydroxy-4-methyl-5-oxooctan-2-yl]-5-methyloxan-2-yl]butanoate
InChi Key
YPZYGIQXBGHDBH-UZHRAPRISA-M
InChi Code
1S/C42H70O11.Na/c1-11-29(38(46)47)31-15-14-23(4)36(50-31)27(8)34(44)26(7)35(45)30(12-2)37-24(5)22-25(6)41(51-37)19-16-32(43)42(53-41)21-20-39(10,52-42)33-17-18-40(48,13-3)28(9)49-33;/h16,19,23-34,36-37,43-44,48H,11-15,17-18,20-22H2,1-10H3,(H,46,47);/q;+1/p-1/t23-,24-,25+,26-,27-,28-,29+,30-,31+,32+,33+,34+,36+,37-,39-,40+,41-,42-;/m0./s1
SMILES Code
CC[C@@H](C([O-])=O)[C@H]1CC[C@H](C)[C@H]([C@H]([C@H](O)[C@@H](C([C@@H]([C@@H]2[C@@H](C)C[C@@H](C)[C@@]3(C=C[C@@H](O)[C@]4(CC[C@@](C)([C@H]5CC[C@@](CC)(O)[C@H](C)O5)O4)O3)O2)CC)=O)C)C)O1.[Na+]
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
772.99
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Li L, Zeng P, Yu L, Yang J, Man J, Zhou L, Zhao L. Salinomycin sodium exerts anti diffuse large B-cell lymphoma activity through inhibition of LRP6-mediated Wnt/β-catenin and mTORC1 signaling. Leuk Lymphoma. 2023 Jun;64(6):1151-1160. doi: 10.1080/10428194.2023.2202291. Epub 2023 Apr 24. PMID: 37092573.
2: EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP); Rychen G, Aquilina G, Azimonti G, Bampidis V, Bastos ML, Bories G, Chesson A, Cocconcelli PS, Flachowsky G, Kolar B, Kouba M, López-Alonso M, López Puente S, Mantovani A, Mayo B, Ramos F, Saarela M, Villa RE, Wallace RJ, Wester P, Brantom P, Halle I, van Beelen P, Holczknecht O, Vettori MV, Gropp J. Safety and efficacy of Sacox® microGranulate (salinomycin sodium) for rabbits for fattening. EFSA J. 2018 Mar 22;16(3):e05209. doi: 10.2903/j.efsa.2018.5209. PMID: 32625842; PMCID: PMC7009495.
3: Zhou J, Sun J, Chen H, Peng Q. Promoted delivery of salinomycin sodium to lung cancer cells by dual targeting PLGA hybrid nanoparticles. Int J Oncol. 2018 Sep;53(3):1289-1300. doi: 10.3892/ijo.2018.4474. Epub 2018 Jul 6. PMID: 30015824.
4: Matsumori N, Morooka A, Murata M. Conformation and location of membrane-bound salinomycin-sodium complex deduced from NMR in isotropic bicelles. J Am Chem Soc. 2007 Dec 5;129(48):14989-95. doi: 10.1021/ja075024l. Epub 2007 Nov 10. PMID: 17994744.
5: Li T, Liu X, Shen Q, Yang W, Huo Z, Liu Q, Jiao H, Chen J. Salinomycin exerts anti-angiogenic and anti-tumorigenic activities by inhibiting vascular endothelial growth factor receptor 2-mediated angiogenesis. Oncotarget. 2016 May 3;7(18):26580-92. doi: 10.18632/oncotarget.8555. PMID: 27058891; PMCID: PMC5042000.
